The PTEN/PI3K/AKT Pathway in vivo, cancer mouse models

Frontiers in Oncology

Volumn 4, Issue SEP, 2014, Pages

  Carnero, Amancio ^a   Paramio, Jesus M ^b,c  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b CIEMAT   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER MODEL; CARCINOGENESIS; CELL CYCLE PROGRESSION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; NONHUMAN; PHENOTYPE; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84907062975     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00252     Document Type: Article

References (147)

1. Abate-Shen, C., Banach-Petrosky, W. A., Sun, X., Economides, K. D., Desai, N., Gregg, J.P. et al. (2003). Nkx3.1; Pten mutant mice develop invasive prostate adenocarcinoma and lymph node metastases. Cancer Res 63: 3886-3890.
2. Ackler, S., Ahmad, S., Tobias, C., Johnson, M. D., Glazer, R. I. (2002). Delayed mammary gland involution in MMTV-AKT1 transgenic mice. Oncogene 21: 198-206.
3. Adams, J.R., Xu, K., Liu, J. C., Agamez, N. M., Loch, A. J., Wong, R. G. et al. (2011).Cooperation between Pik3ca and p53 mutations in mouse mammary tumor formation. Cancer Res 71: 2706-2717.
4. Anderson, P. D., McKissic, S. A., Logan, M., Roh, M., Franco, O. E., Wang, J. et al. (2012).Nkx3.1 and Myc crossregulate shared target genes in mouse and human prostate tumorigenesis. J Clin Invest 122: 1907-1919.
5. Asano, T., Yao, Y., Zhu, J., Li, D., Abbruzzese, J. L., Reddy, S. A. (2004). The PI 3-kinase/Aktsignaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-kappaB and c-Myc in pancreatic cancer cells. Oncogene 23:8571-8580.
6. Backman, S. A., Stambolic, V., Suzuki, A., Haight, J., Elia, A., Pretorius, J. et al. (2001).Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 29: 396-403.
7. Bachman, K. E., Argani, P., Samuels, Y., Silliman, N., Ptak, J., Szabo, S. et al. (2004). The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biol Ther 3: 772-775.
8. Bader, A. G., Kang, S., Vogt, P. K. (2006). Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc Natl Acad Sci U S A 103: 1475-1479.
9. Baker, S. J. (2007). PTEN enters the nuclear age. Cell 128: 25-28.
10. Bayascas, J. R., Leslie, N. R., Parsons, R., Fleming, S., Alessi, D. R. (2005). Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN(+/-) mice. Curr Biol 15: 1839-1846.
11. Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K. et al.(2007). A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer cell 12: 395-402.
12. Bhatia-Gaur, R., Donjacour, A. A., Sciavolino, P. J., Kim, M., Desai, N., Young, P. et al.(1999). Roles for Nkx3.1 in prostate development and cancer. Genes Dev 13: 966-977.
13. Blanco-Aparicio, C., Renner, O., Leal, J. F., Carnero, A. (2007). PTEN, more than the AKT pathway. Carcinogenesis 28: 1379-1386.
14. Blanco-Aparicio, C., Canamero, M., Cecilia, Y., Pequeno, B., Renner, O., Ferrer, I. et al.(2010). Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. PLoS ONE 5: e9305.
15. Bornachea, O., Santos, M., Martinez-Cruz, A. B., Garcia-Escudero, R., Duenas, M., Costa, C. et al. (2012). EMT and induction of miR-21 mediate metastasis development in Trp53-deficient tumours. Sci Rep 2: 434.
16. Boyault, S., Drouet, Y., Navarro, C., Bachelot, T., Lasset, C., Treilleux, I. et al. (2012).Mutational characterization of individual breast tumors: TP53 and PI3K pathway genes are frequently and distinctively mutated in different subtypes. Breast cancer research and treatment 132: 29-39.
17. Broderick, D. K., Di, C., Parrett, T. J., Samuels, Y. R., Cummins, J. M., McLendon, R. E. et al.(2004). Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048-5050.
18. Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S. et al. (2004). Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 64: 7678-7681.
19. Cancer Genome Atlas, N. (2012). Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
20. Carnero, A., Blanco-Aparicio, C., Renner, O., Link, W., Leal, J. F. (2008). The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8: 187-198.
21. Carnero, A. (2009). The PKB/AKT Pathway in Cancer. Current Pharmacological Design 17: 1435-1449.
22. Carpten, J. D., Faber, A. L., Horn, C., Donoho, G. P., Briggs, S. L., Robbins, C. M. et al.(2007). A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439-444.
23. Carracedo, A., Pandolfi, P. P. (2008). The PTEN-PI3K pathway: of feedbacks and crosstalks. Oncogene 27: 5527-5541.
24. Carver, B. S., Pandolfi, P. P. (2006). Mouse modeling in oncologic preclinical and translational research. Clin Cancer Res 12: 5305-5311.
25. Costa, C., Santos, M., Segrelles, C., Duenas, M., Lara, M. F., Agirre, X. et al. (2012). A novel tumor suppressor network in squamous malignancies. Sci Rep 2: 828.
26. Chang, C. J., Freeman, D. J., Wu, H. (2004). PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 279: 29841-29848.
27. Chen, Z., Trotman, L. C., Shaffer, D., Lin, H. K., Dotan, Z. A., Niki, M. et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725-730.
28. Dahia, P. L. (2000). PTEN, a unique tumor suppressor gene. Endocr Relat Cancer 7: 115-129.
29. Daikoku, T., Hirota, Y., Tranguch, S., Joshi, A. R., DeMayo, F. J., Lydon, J. P. et al. (2008).Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 68: 5619-5627.
30. Datta, S. R., Brunet, A., Greenberg, M. E. (1999). Cellular survival: a play in three Akts. Genes Dev 13: 2905-2927.
31. Deng, C. X., Brodie, S. G. (2001). Knockout mouse models and mammary tumorigenesis. Semin Cancer Biol 11: 387-394.
32. Di Cristofano, A., Pesce, B., Cordon-Cardo, C., Pandolfi, P. P. (1998). Pten is essential for embryonic development and tumour suppression. Nat Genet 19: 348-355.
33. Ding, Z., Wu, C. J., Chu, G. C., Xiao, Y., Ho, D., Zhang, J. et al. (2011). SMAD4-dependent
34. barrier constrains prostate cancer growth and metastatic progression. Nature 470: 269-273.
35. Ding, Z., Wu, C. J., Jaskelioff, M., Ivanova, E., Kost-Alimova, M., Protopopov, A. et al.(2012). Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell 148: 896-907.
36. Downward, J. (2003). Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3: 11-22.
37. Downward, J. (2004). PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 15: 177-182.
38. Duenas, M., Martinez-Fernandez, M., Garcia-Escudero, R., Villacampa, F., Marques, M., Saiz-Ladera, C. et al. (2013). PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors. Mol Carcinog.
39. Dummler, B., Tschopp, O., Hynx, D., Yang, Z. Z., Dirnhofer, S., Hemmings, B. A. (2006). Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol Cell Biol 26: 8042-8051.
40. Dummler, B., Hemmings, B. A. (2007). Physiological roles of PKB/Akt isoforms in development and disease. Biochem Soc Trans 35: 231-235.
41. Dunbar, M. E., Wysolmerski, J. J. (2001). Mammary ductal and alveolar development:lesson learned from genetically manipulated mice. Microsc Res Tech 52: 163-170.
42. Engelman, J. A., Chen, L., Tan, X., Crosby, K., Guimaraes, A. R., Upadhyay, R. et al.(2008). Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14: 1351-1356.
43. Engelman, J. A. (2009). Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-562.
44. Eser, S., Reiff, N., Messer, M., Seidler, B., Gottschalk, K., Dobler, M. et al. (2013). Selective requirement of PI3K/PDK1 signaling for Kras oncogene-driven pancreatic cell plasticity and cancer. Cancer Cell 23: 406-420.
45. Freeman, D., Lesche, R., Kertesz, N., Wang, S., Li, G., Gao, J. et al. (2006). Genetic background controls tumor development in PTEN-deficient mice. Cancer Res 66: 6492-6496.
46. Freeman, D. J., Li, A. G., Wei, G., Li, H. H., Kertesz, N., Lesche, R. et al. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3: 117-130.
47. Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., Abate-Shen, C. (2006).Emergence of androgen independence at early stages of prostate cancer progression in Nkx3.1; Pten mice. Cancer Res 66: 7929-7933.
48. Garcia-Rostan, G., Costa, A. M., Pereira-Castro, I., Salvatore, G., Hernandez, R., Hermsem, M. J. et al. (2005). Mutation of the PIK3CA gene in anaplastic thyroid cancer. Cancer Res 65: 10199-10207.
49. Gil, A., Andres-Pons, A., Pulido, R. (2007). Nuclear PTEN: a tale of many tails. Cell Death Differ 14: 395-399.
50. Gottlieb, T. M., Leal, J. F., Seger, R., Taya, Y., Oren, M. (2002). Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis. Oncogene 21:1299-1303.
51. Graupera, M., Guillermet-Guibert, J., Foukas, L. C., Phng, L. K., Cain, R. J., Salpekar, A. et al. (2008). Angiogenesis selectively requires the p110alpha isoform of PI3K to control endothelial cell migration. Nature 453: 662-666.
52. Gupta, S., Ramjaun, A. R., Haiko, P., Wang, Y., Warne, P. H., Nicke, B. et al. (2007).Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell 129: 957-968.
53. Hernando, E., Charytonowicz, E., Dudas, M. E., Menendez, S., Matushanksy, I., Mills, J. et al. (2007). The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med.
54. Holland, E. C., Celestino, J., Dai, C., Schaefer, L., Sawaya, R. E., Fuller, G. N. (2000).Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55-57.
55. Hollestelle, A., Elstrodt, F., Nagel, J. H., Kallemeijn, W. W., Schutte, M. (2007).Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Molecular cancer research: MCR 5: 195-201.
56. Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., Muller, W. J. (2001). Activation of Akt(protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression. Mol Cell Biol 21: 2203-2212.
57. Hutchinson, J. N., Jin, J., Cardiff, R. D., Woodgett, J. R., Muller, W. J. (2004). Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res 64: 3171-3178.
58. Inoue, K., Fry, E. A., Taneja, P. (2013). Recent progress in mouse models for tumor suppressor genes and its implications in human cancer. Clin Med Insights Oncol 7: 103-122.
59. Iwanaga, K., Yang, Y., Raso, M. G., Ma, L., Hanna, A. E., Thilaganathan, N. et al. (2008).Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res 68: 1119-1127.
60. Jensen, J. D., Knoop, A., Laenkholm, A. V., Grauslund, M., Jensen, M. B., Santoni-Rugiu, E. et al. (2012). PIK3CA mutations, PTEN, and pHER2 expression and impact on outcome in HER2-positive early-stage breast cancer patients treated with adjuvant chemotherapy and trastuzumab. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 23: 2034-2042.
61. Jia, S., Liu, Z., Zhang, S., Liu, P., Zhang, L., Lee, S. H. et al. (2008). Essential roles of PI(3)Kp110beta in cell growth, metabolism and tumorigenesis. Nature 454: 776-779.
62. Jimenez, C., Jones, D. R., Rodriguez-Viciana, P., Gonzalez-Garcia, A., Leonardo, E., Wennstrom, S. et al. (1998). Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase. Embo J 17: 743-753.
63. Ju, X., Katiyar, S., Wang, C., Liu, M., Jiao, X., Li, S. et al. (2007). Akt1 governs breast cancer progression in vivo. Proc Natl Acad Sci U S A 104: 7438-7443.
64. Kandel, E. S., Hay, N. (1999). The regulation and activities of the multifunctional serine/threonine kinase Akt/PKB. Exp Cell Res 253: 210-229.
65. Kang, S., Bader, A. G., Vogt, P. K. (2005). Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc Natl Acad Sci U S A 102: 802-807.
66. Kennedy, A. L., Morton, J. P., Manoharan, I., Nelson, D. M., Jamieson, N. B., Pawlikowski, J. S. et al. (2011). Activation of the PIK3CA/AKT pathway suppresses senescence induced by an activated RAS oncogene to promote tumorigenesis. Mol Cell 42: 36-49.
67. Kim, J., Eltoum, I. E., Roh, M., Wang, J., Abdulkadir, S. A. (2009). Interactions between cells with distinct mutations in c-MYC and Pten in prostate cancer. PLoS Genet 5:e1000542.
68. Kirkegaard, T., Witton, C. J., McGlynn, L. M., Tovey, S. M., Dunne, B., Lyon, A. et al.(2005). AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-146.
69. Kishimoto, H., Hamada, K., Saunders, M., Backman, S., Sasaki, T., Nakano, T. et al. (2003).Physiological functions of Pten in mouse tissues. Cell Struct Funct 28: 11-21.
70. Klarenbeek, S., van Miltenburg, M. H., Jonkers, J. (2013). Genetically engineered mouse models of PI3K signaling in breast cancer. Mol Oncol 7: 146-164.
71. Kwon, C. H., Zhao, D., Chen, J., Alcantara, S., Li, Y., Burns, D. K. et al. (2008). Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res 68:3286-3294.
72. Li, A. G., Piluso, L. G., Cai, X., Wei, G., Sellers, W. R., Liu, X. (2006). Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 23: 575-587.
73. Li, G., Robinson, G. W., Lesche, R., Martinez-Diaz, H., Jiang, Z., Rozengurt, N. et al. (2002).Conditional loss of PTEN leads to precocious development and neoplasia in the mammary gland. Development 129: 4159-4170.
74. Li, H., Zhu, R., Wang, L., Zhu, T., Li, Q., Chen, Q. et al. (2010). PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast. Experimental and molecular pathology 88: 150-155.
75. Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I. et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-1947.
76. Li, Y., Podsypanina, K., Liu, X., Crane, A., Tan, L. K., Parsons, R. et al. (2001). Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2: 2.
77. Lian, Z., Di Cristofano, A. (2005). Class reunion: PTEN joins the nuclear crew. Oncogene 24: 7394-7400.
78. Liaw, D., Marsh, D. J., Li, J., Dahia, P. L., Wang, S. I., Zheng, Z. et al. (1997). Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet 16: 64-67.
79. Lindsay, Y., McCoull, D., Davidson, L., Leslie, N. R., Fairservice, A., Gray, A. et al. (2006).Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 119: 5160-5168.
80. Link, W., Rosado, A., Fominaya, J., Thomas, J. E., Carnero, A. (2005). Membrane localization of all class I PI 3-kinase isoforms suppresses c-Myc-induced apoptosis in Rat1 fibroblasts via Akt. J Cell Biochem 95: 979-989.
81. Liu, P., Cheng, H., Santiago, S., Raeder, M., Zhang, F., Isabella, A. et al. (2011). Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathwaydependent and PI3K pathway-independent mechanisms. Nat Med 17: 1116-1120.
82. Lopez-Knowles, E., O'Toole, S. A., McNeil, C. M., Millar, E. K., Qiu, M. R., Crea, P. et al.(2010). PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. International journal of cancer Journal international du cancer 126: 1121-1131.
83. Maehama, T., Dixon, J. E. (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 273:13375-13378.
84. Majumder, P. K., Yeh, J. J., George, D. J., Febbo, P. G., Kum, J., Xue, Q. et al. (2003).Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT model. Proc Natl Acad Sci U S A 100: 7841-7846.
85. Majumder, P. K., Grisanzio, C., O'Connell, F., Barry, M., Brito, J. M., Xu, Q. et al. (2008). A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14: 146-155.
86. Manning, B. D., Cantley, L. C. (2007). AKT/PKB signaling: navigating downstream. Cell 129: 1261-1274.
87. Marsh, D. J., Kum, J. B., Lunetta, K. L., Bennett, M. J., Gorlin, R. J., Ahmed, S. F. et al.(1999). PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 8: 1461-1472.
88. Martinez-Cruz, A. B., Santos, M., Lara, M. F., Segrelles, C., Ruiz, S., Moral, M. et al. (2008).Spontaneous squamous cell carcinoma induced by the somatic inactivation of retinoblastoma and Trp53 tumor suppressors. Cancer Res 68: 683-692.
89. Martinez-Cruz, A. B., Santos, M., Garcia-Escudero, R., Moral, M., Segrelles, C., Lorz, C. et al. (2009). Spontaneous tumor formation in Trp53-deficient epidermis mediated by chromosomal instability and inflammation. Anticancer Res 29: 3035-3042.
90. Mayo, L. D., Donner, D. B. (2001). A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus. Proc Natl Acad Sci U S A 98:11598-11603.
91. Meyer, D. S., Brinkhaus, H., Muller, U., Muller, M., Cardiff, R. D., Bentires-Alj, M. (2011).Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Res 71: 4344-4351.
92. Meyer, D. S., Koren, S., Leroy, C., Brinkhaus, H., Muller, U., Klebba, I. et al. (2013).Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. Oncogenesis 2: e74.
93. Moral, M., Segrelles, C., Lara, M. F., Martinez-Cruz, A. B., Lorz, C., Santos, M. et al. (2009).Akt activation synergizes with Trp53 loss in oral epithelium to produce a novel mouse model for head and neck squamous cell carcinoma. Cancer Res 69: 1099-1108.
94. Mulholland, D. J., Tran, L. M., Li, Y., Cai, H., Morim, A., Wang, S. et al. (2011). Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. Cancer Cell 19: 792-804.
95. Myers, M. P., Stolarov, J. P., Eng, C., Li, J., Wang, S. I., Wigler, M. H. et al. (1997). P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci U S A 94: 9052-9057.
96. Myers, M. P., Pass, I., Batty, I. H., Van der Kaay, J., Stolarov, J. P., Hemmings, B. A. et al.(1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 95: 13513-13518.
97. Nakayama, K., Nakayama, N., Kurman, R. J., Cope, L., Pohl, G., Samuels, Y. et al. (2006).Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5: 779-785.
98. Narlik-Grassow, M., Blanco-Aparicio, C., Cecilia, Y., Peregrina, S., Garcia-Serelde, B., Munoz-Galvan, S. et al. (2012). The essential role of PIM kinases in sarcoma growth and bone invasion. Carcinogenesis 33: 1479-1486.
99. Narlik-Grassow, M., Blanco-Aparicio, C., Cecilia, Y., Perez, M., Munoz-Galvan, S., Canamero, M. et al. (2013). Conditional transgenic expression of PIM1 kinase in prostate induces inflammation-dependent neoplasia. PLoS ONE 8: e60277.
100. Narlik-Grassow, M., Blanco-Aparicio, C., Cecilia, Y., Perez, M., Munoz-Galvan, S., Canamero, M. et al. (2014). Pim1 Kinase Cooperates with Hormone Treatment to Promote Bladder and Ureteral Urothelial Hyperplasia. J Carcinog Mutagen 5: 2-6.Nelen, M. R., van Staveren, W. C., Peeters, E. A., Hassel, M. B., Gorlin, R. J., Hamm, H. et al. (1997). Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. Hum Mol Genet 6: 1383-1387.
101. Okano, J., Snyder, L., Rustgi, A. K. (2003). Genetic alterations in esophageal cancer. Methods Mol Biol 222: 131-145.
102. Okumura, K., Mendoza, M., Bachoo, R. M., DePinho, R. A., Cavenee, W. K., Furnari, F. B.(2006). PCAF modulates PTEN activity. J Biol Chem 281: 26562-26568.
103. Oren, M., Damalas, A., Gottlieb, T., Michael, D., Taplick, J., Leal, J. F. et al. (2002).Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 64: 865-871.
104. Paramio, J. M., Navarro, M., Segrelles, C., Gomez-Casero, E., Jorcano, J. L. (1999). PTEN tumour suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 18: 7462-7468.
105. Parsons, D. W., Wang, T. L., Samuels, Y., Bardelli, A., Cummins, J. M., DeLong, L. et al.(2005). Colorectal cancer: mutations in a signalling pathway. Nature 436: 792.
106. Plas, D. R., Thompson, C. B. (2005). Akt-dependent transformation: there is more to growth than just surviving. Oncogene 24: 7435-7442.
107. Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M. et al.(1999). Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 96: 1563-1568.
108. Radu, A., Neubauer, V., Akagi, T., Hanafusa, H., Georgescu, M. M. (2003). PTEN induces cell cycle arrest by decreasing the level and nuclear localization of cyclin D1. Mol Cell Biol 23: 6139-6149.
109. Renner, O., Fominaya, J., Alonso, S., Blanco-Aparicio, C., Leal, J. F., Carnero, A. (2007).Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate. Carcinogenesis 28: 1418-1425.
110. Renner, O., Blanco-Aparicio, C., Carnero, A. (2008a). Genetic modelling of the PTEN/AKT pathway in cancer research. Clin Transl Oncol 10: 618-627.
111. Renner, O., Blanco-Aparicio, C., Grassow, M., Canamero, M., Leal, J. F., Carnero, A.(2008b). Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation. Cancer Res 68:9643-9653.
112. Renner, O., Carnero, A. (2009). Mouse models to decipher the PI3K signaling network in human cancer. Curr Mol Med 9: 612-625.
113. Saal, L. H., Holm, K., Maurer, M., Memeo, L., Su, T., Wang, X. et al. (2005). PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res 65: 2554-2559.
114. Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q. B., Maurer, M. et al.(2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences of the United States of America 104: 7564-7569.
115. Saal, L. H., Gruvberger-Saal, S. K., Persson, C., Lovgren, K., Jumppanen, M., Staaf, J. et al. (2008). Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair. Nat Genet 40: 102-107.
116. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S. et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
117. Schade, B., Rao, T., Dourdin, N., Lesurf, R., Hallett, M., Cardiff, R. D. et al. (2009). PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis. J Biol Chem 284: 19018-19026.
118. Schrager, C. A., Schneider, D., Gruener, A. C., Tsou, H. C., Peacocke, M. (1998). Clinical and pathological features of breast disease in Cowden's syndrome: an underrecognized syndrome with an increased risk of breast cancer. Hum Pathol 29: 47-53.
119. Schwertfeger, K. L., Richert, M. M., Anderson, S. M. (2001). Mammary gland involution is delayed by activated Akt in transgenic mice. Mol Endocrinol 15: 867-881.
120. Segrelles, C., Ruiz, S., Perez, P., Murga, C., Santos, M., Budunova, I. V. et al. (2002).Functional roles of Akt signaling in mouse skin tumorigenesis. Oncogene 21: 53-64.
121. Segrelles, C., Moral, M., Lara, M. F., Ruiz, S., Santos, M., Leis, H. et al. (2006). Molecular determinants of Akt-induced keratinocyte transformation. Oncogene 25: 1174-1185.
122. Segrelles, C., Lu, J., Hammann, B., Santos, M., Moral, M., Cascallana, J. L. et al. (2007).
123. Deregulated activity of Akt in epithelial basal cells induces spontaneous tumors and heightened sensitivity to skin carcinogenesis. Cancer Res 67: 10879-10888.
124. Segrelles, C., Garcia-Escudero, R., Garin, M. I., Aranda, J. F., Hernandez, P., Ariza, J. M. et al. (2014). Akt signalling leads to stem cell activation and promotes tumour development in epidermis. Stem Cells.
125. Shioi, T., Kang, P. M., Douglas, P. S., Hampe, J., Yballe, C. M., Lawitts, J. et al. (2000). The conserved phosphoinositide 3-kinase pathway determines heart size in mice. Embo J 19: 2537-2548.
126. Stambolic, V., Tsao, M. S., Macpherson, D., Suzuki, A., Chapman, W. B., Mak, T. W.(2000). High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 60: 3605-3611.
127. Stambolic, V., MacPherson, D., Sas, D., Lin, Y., Snow, B., Jang, Y. et al. (2001). Regulation of PTEN transcription by p53. Mol Cell 8: 317-325.
128. Stanger, B. Z., Stiles, B., Lauwers, G. Y., Bardeesy, N., Mendoza, M., Wang, Y. et al. (2005).Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8: 185-195.
129. Stemke-Hale, K., Gonzalez-Angulo, A. M., Lluch, A., Neve, R. M., Kuo, W. L., Davies, M. et al. (2008). An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer research 68: 6084-6091.
130. Stiles, B., Groszer, M., Wang, S., Jiao, J., Wu, H. (2004). PTENless means more. Dev Biol 273: 175-184.Stokoe, D. (2001). Pten. Curr Biol 11: R502.
131. Suzuki, A., de la Pompa, J. L., Stambolic, V., Elia, A. J., Sasaki, T., del Barco Barrantes, I. et al. (1998). High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 8: 1169-1178.
132. Suzuki, A., Yamaguchi, M. T., Ohteki, T., Sasaki, T., Kaisho, T., Kimura, Y. et al. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14: 523-534.
133. Tikoo, A., Roh, V., Montgomery, K. G., Ivetac, I., Waring, P., Pelzer, R. et al. (2012).Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERalpha-positive tumors. PLoS ONE 7: e36924.
134. Vivanco, I., Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489-501.
135. Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J. et al. (2003). Prostatespecific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4: 209-221.
136. Webster, M. A., Hutchinson, J. N., Rauh, M. J., Muthuswamy, S. K., Anton, M., Tortorice, C.G. et al. (1998). Requirement for both Shc and phosphatidylinositol 3' kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 18:2344-2359.
137. Weng, L., Brown, J., Eng, C. (2001). PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 10: 237-242.
138. Xiao, A., Wu, H., Pandolfi, P. P., Louis, D. N., Van Dyke, T. (2002). Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1: 157-168.
139. Xiao, A., Yin, C., Yang, C., Di Cristofano, A., Pandolfi, P. P., Van Dyke, T. (2005). Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 65: 5172-5180.
140. Xing, D., Orsulic, S. (2005). A genetically defined mouse ovarian carcinoma model for the molecular characterization of pathway-targeted therapy and tumor resistance. Proc Natl Acad Sci U S A 102: 6936-6941.
141. Yao, D., Alexander, C. L., Quinn, J. A., Porter, M. J., Wu, H., Greenhalgh, D. A. (2006).PTEN loss promotes rasHa-mediated papillomatogenesis via dual up-regulation of AKT activity and cell cycle deregulation but malignant conversion proceeds via PTENassociated pathways. Cancer Res 66: 1302-1312.
142. Yuan, T. L., Cantley, L. C. (2008). PI3K pathway alterations in cancer: variations on a theme. Oncogene 27: 5497-5510.
143. Yuan, W., Stawiski, E., Janakiraman, V., Chan, E., Durinck, S., Edgar, K. A. et al. (2013).Conditional activation of Pik3ca(H1047R) in a knock-in mouse model promotes mammary tumorigenesis and emergence of mutations. Oncogene 32: 318-326.
144. Zhao, H., Cui, Y., Dupont, J., Sun, H., Hennighausen, L., Yakar, S. (2005a). Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits wnt-1-induced mammary tumorigenesis. Cancer Res 65: 6864-6873.
145. Zhao, J. J., Liu, Z., Wang, L., Shin, E., Loda, M. F., Roberts, T. M. (2005b). The oncogenic properties of mutant p110alpha and p110beta phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc Natl Acad Sci U S A 102: 18443-18448.
146. Zhao, L., Vogt, P. K. (2008). Class I PI3K in oncogenic cellular transformation. Oncogene 27: 5486-5496.
147. Zhao, L., Vogt, P. K. (2010). Hot-spot mutations in p110alpha of phosphatidylinositol 3-kinase (pI3K): differential interactions with the regulatory subunit p85 and with RAS. CellCycle 9: 596-600.